U Klotz

Summary

Affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
Country: Germany

Publications

  1. ncbi Variability in response to cardiovascular drugs
    Ehab S El Desoky
    Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
    Curr Clin Pharmacol 1:35-46. 2006
  2. ncbi Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Clin Pharmacol Ther 44:297-302. 2006
  3. doi Paracetamol (acetaminophen) - a popular and widely used nonopioid analgesic
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany
    Arzneimittelforschung 62:355-9. 2012
  4. doi Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 59:271-82. 2009
  5. ncbi Pharmacological comparison of the statins
    Ulrich Klotz
    Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 53:605-11. 2003
  6. ncbi Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 53:681-7. 2003
  7. ncbi [Drug interactions. Mechanisms and clinical relevance]
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart
    Internist (Berl) 44:1444-9. 2003
  8. ncbi CYP2C19 polymorphism and proton pump inhibitors
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, D 70376 Stuttgart, Germany
    Basic Clin Pharmacol Toxicol 95:2-8. 2004
  9. ncbi Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Adv Drug Deliv Rev 57:267-79. 2005
  10. ncbi Colonic targeting of aminosalicylates for the treatment of ulcerative colitis
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Dig Liver Dis 37:381-8. 2005

Collaborators

Detail Information

Publications62

  1. ncbi Variability in response to cardiovascular drugs
    Ehab S El Desoky
    Pharmacology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
    Curr Clin Pharmacol 1:35-46. 2006
    ..Cardiovascular pharmacogenomics is a new field that focus on the roles of genetic polymorphisms in drug metabolizing enzymes and drug targets in development of variable drug response...
  2. ncbi Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Clin Pharmacol Ther 44:297-302. 2006
    ..Thus, a genotype-adjusted dosage regimen will improve therapeutic efficacy of PPIs...
  3. doi Paracetamol (acetaminophen) - a popular and widely used nonopioid analgesic
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany
    Arzneimittelforschung 62:355-9. 2012
    ..Keeping this limitation in mind paracetamol still represents a valuable first-line agent in the pharmacological management of pain...
  4. doi Proton pump inhibitors--their pharmacological impact on the clinical management of acid-related disorders
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 59:271-82. 2009
    ..In general, the clinical benefits of PPI are well documented but some patients can be regarded as non-responders and thus represent a challenge for future clinical research...
  5. ncbi Pharmacological comparison of the statins
    Ulrich Klotz
    Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 53:605-11. 2003
    ..Selection of a particular drug should be primarily based on clinical outcome data. However, costs and in certain situations the pharmacokinetic profile including the interaction potential of the statins should be taken into account...
  6. ncbi Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 53:681-7. 2003
    ..Therefore it represents a drug of first choice if moderate to severe pain states have to be treated in pediatric, adult and elderly patients including those with poor cardiopulmonary function...
  7. ncbi [Drug interactions. Mechanisms and clinical relevance]
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart
    Internist (Berl) 44:1444-9. 2003
    ..Both pharmacokinetic processes can be induced or inhibited by numerous agents. Taking proton pump inhibitors as an example it could be shown that the various compounds can differ in their interaction potential...
  8. ncbi CYP2C19 polymorphism and proton pump inhibitors
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, D 70376 Stuttgart, Germany
    Basic Clin Pharmacol Toxicol 95:2-8. 2004
    ..Therefore initial genotyping for this enzyme and higher dosage in extensive metabolizers is likely to improve the clinical efficacy of proton pump inhibitors...
  9. ncbi Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Adv Drug Deliv Rev 57:267-79. 2005
    ..It can be assumed that for any novel therapeutic principle in IBD the approach of topical delivery will be also tried...
  10. ncbi Colonic targeting of aminosalicylates for the treatment of ulcerative colitis
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Dig Liver Dis 37:381-8. 2005
    ..Consequently, selection of a particular agent should be based primarily on clinical efficacy, profile of adverse effects, patients' acceptance and economic considerations...
  11. ncbi [Pharmacology of proton pump inhibitors]
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart
    Pharm Unserer Zeit 34:200-4. 2005
  12. ncbi Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Clin Pharmacol Ther 44:478-83. 2006
    ..In conclusion, ziconotide is a new and valuable alternative analgesic for the acute and long-term treatment of severe pain, especially in patients refractory to opioids...
  13. ncbi The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Germany
    Clin Pharmacokinet 46:271-9. 2007
    ..Nevertheless, pharmacogenetics and pharmacogenomics can offer some novel contributions when attempts are made to maximise drug efficacy and enhance drug safety...
  14. ncbi Antiarrhythmics: elimination and dosage considerations in hepatic impairment
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, GermanyUniversity of Tübingen, Tubingen, Germany
    Clin Pharmacokinet 46:985-96. 2007
    ..In conclusion, hepatic impairment decreases the elimination of many antiarrhythmics to such an extent that dosage reductions are highly recommended in such populations, especially in patients with cirrhosis...
  15. doi Pharmacokinetics and drug metabolism in the elderly
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Drug Metab Rev 41:67-76. 2009
    ..In conclusion, age-related physiological and pharmacokinetic changes as well as the presence of comorbidity and polypharmacy will complicate drug therapy in the elderly...
  16. ncbi Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Arzneimittelforschung 52:155-61. 2002
    ..In addition to these putative pharmacokinetic interactions also pharmacodynamic interactions with other cardiovascular active substances might be considered and some caution should be exercised if vasodilators are given as comedication...
  17. ncbi Telomere length in different tissues of elderly patients
    U Friedrich
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
    Mech Ageing Dev 119:89-99. 2000
    ..Furthermore, our results indicate that TRF measurement in easily accessible tissues such as blood could serve as a surrogate parameter for the relative telomere length in other tissues...
  18. ncbi Clinical pharmacokinetics and use of infliximab
    Ulrich Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 46:645-60. 2007
    ....
  19. ncbi Pharmacokinetic considerations in the eradication of Helicobacter pylori
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Germany
    Clin Pharmacokinet 38:243-70. 2000
    ..When addressing the clinically important questions of the efficacy, safety and costs of the recommended regimens, the impact of drug disposition on H. pylori eradication should not be neglected...
  20. ncbi [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations]
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart
    Med Klin (Munich) 94:16-22. 1999
    ..This review describes the various pharmacokinetic and (patho)physiologic factors and their impact on drug delivery and biological availability of the different 5-ASA and budesonide preparations...
  21. ncbi The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Eur J Clin Pharmacol 56:353-62. 2000
    ..To discuss the pharmacological properties of aminosalicylates and their potential value in the treatment of chronic inflammatory bowel disease (IBD)...
  22. ncbi Pharmacokinetic considerations in the treatment of inflammatory bowel disease
    M Schwab
    Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 40:723-51. 2001
    ..No accumulation was observed when it was administered at intervals of 4 or 8 weeks. Methotrexate may reduce the clearance of infliximab from serum...
  23. doi Efficient telomerase inhibition in human non-small cell lung cancer cells by liposomal delivery of 2'-O-methyl-RNA
    Julia Beisner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Stuttgart, Germany
    J Pharm Sci 98:1765-74. 2009
    ....
  24. ncbi Screening of telomerase inhibitors
    Elke Kleideiter
    Dr Margarete Fiscer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Methods Mol Biol 405:167-80. 2007
    ..Subsequently, telomerase activity of A-549 cells was investigated using the TRAP assay, and telomere length of samples was assessed by telomere restriction fragment (TRF) Southern blot analysis...
  25. ncbi Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 78:627-34. 2005
    ..We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype...
  26. ncbi Drug metabolism and drug interactions in the elderly
    C Herrlinger
    Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany
    Best Pract Res Clin Gastroenterol 15:897-918. 2001
    ..However, since elderly patients consume a greater proportional share of drugs, they represent a population at risk for interactions. Awareness of this clinical problem may help to diminish those risks...
  27. ncbi Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
    C Pauli-Magnus
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 364:551-7. 2001
    ..In summary, our data provide evidence that proton pump inhibitors are substrates and inhibitors of P-glycoprotein. These findings might explain some of the drug interactions with proton pump inhibitors observed in vivo...
  28. ncbi P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin
    C Pauli-Magnus
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 363:337-43. 2001
    ..In summary, these data provide evidence that not only digoxin, but also digitoxin, alpha-methyldigoxin and beta-acetyldigoxin are substrates of P-glycoprotein...
  29. ncbi CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori
    Matthias Schwab
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    Clin Pharmacol Ther 76:201-9. 2004
    ..This study tests the hypothesis that CYP2C19 wild type ( wt/wt ) in white patients is also associated with a higher probability of treatment failure...
  30. ncbi Nocturnal doses of ranitidine and nizatidine do not affect the disposition of diazepam
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, FRG
    J Clin Pharmacol 27:210-2. 1987
    ..Thus, it can be concluded that concomitant once-daily dosing (300 mg nocturnally) with ranitidine or nizatidine does not impair hepatic drug metabolism...
  31. doi The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid)
    U Klotz
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Germany
    Arzneimittelforschung 62:53-8. 2012
    ..It is anticipated that more selective drug targeting, including galenic innovations and an optimized dosaging schedule, could result in some improvement of the wide use of 5-ASA...
  32. ncbi Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone
    K Dilger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacol Ther 67:512-20. 2000
    ..Propafenone was chosen as a model drug because of its complex metabolism that permits the simultaneous in vivo assessment of induction of phase 1 and phase 2 pathways...
  33. ncbi Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori
    S Ammon
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Robert Bosch Hospital, Stuttgart, Germany
    Aliment Pharmacol Ther 14:759-66. 2000
    ..The success of eradication therapy for Helicobacter pylori might be affected by the age of patients...
  34. ncbi Benzodiazepines: are they of natural origin?
    E Unseld
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, West Germany
    Pharm Res 6:1-3. 1989
    ..Whether the measured low concentrations (ranging from 0.01 up to 600 ng/g wet weight) have any biological role or clinical significance remains to be determined...
  35. ncbi Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry
    Ute Hofmann
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 831:85-90. 2006
    ..The method was successfully applied to the determination of pharmacokinetic parameters of esomeprazole and the two major metabolites after a single dose and under steady state conditions...
  36. ncbi Osteoarthritis of the knee--clinical assessments and inflammatory markers
    Stefanie S Brenner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Osteoarthritis Cartilage 12:469-75. 2004
    ..The present cross sectional study was performed to test the hypothesis that in osteoarthritis (OA) of the knee severity of this disease is related to local levels of inflammatory metabolites and their corresponding enzymes...
  37. doi Nanoparticle mediated delivery of 2'-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells
    Julia Beisner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tuebingen, Stuttgart, Germany
    Lung Cancer 68:346-54. 2010
    ....
  38. ncbi Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors
    Kamilla Piotrowska
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Lab Invest 85:1565-9. 2005
    ....
  39. ncbi Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease
    H Xin
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Aliment Pharmacol Ther 21:1105-9. 2005
    ..Thus, during treatment with azathioprine or mercaptopurine, both metabolized by thiopurine S-methyltransferase, sulfasalazine or 5-aminosalicylate could modify the action of azathioprine/mercaptopurine...
  40. pmc Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease
    M Butscheid
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    J Clin Pathol 60:415-8. 2007
    ....
  41. ncbi Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib
    Stefanie S Brenner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 42:283-92. 2003
    ....
  42. ncbi Detection of desmethyldiazepam and diazepam in brain of different species and plants
    E Unseld
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Federal Republic of Germany
    Biochem Pharmacol 38:2473-8. 1989
    ..This would suggest that DD and D might be of natural origin and incorporated via the foodchain into the animal and human body. The biological role or clinical relevance of these intriguing findings need still to be elucidated...
  43. ncbi Telomerase activity in cell lines of pediatric soft tissue sarcomas
    Elke Kleideiter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pediatr Res 54:718-23. 2003
    ..Taken together, our cell line experiments imply that telomerase activity might be a biologic marker for stratification between STS with different clinical prognosis...
  44. ncbi Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing
    Alexander Teml
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Clin Pharmacokinet 46:187-208. 2007
    ..To improve response rates in thiopurine therapy of IBD, comprehensive analyses including metabolic patterns and genome-wide profiling in patients with azathioprine/mercaptopurine treatment are required to identify novel candidate genes...
  45. ncbi Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
    Rajinder K Bhardwaj
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Pharmacol Exp Ther 302:645-50. 2002
    ....
  46. ncbi Clinical use and pharmacological properties of selective COX-2 inhibitors
    Shaojun Shi
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Auerbachstrasse 112, 70376, Stuttgart, Germany
    Eur J Clin Pharmacol 64:233-52. 2008
    ..Monitoring of kidney function and blood pressure appears advisable. It is hoped that further controlled studies can better define the therapeutic place of the coxibs...
  47. ncbi [Drug interactions--their impact on safe drug therapy in the example of the new thiazolidinedione group (glitazone)]
    U Klotz
    , Stuttgart
    Arzneimittelforschung 51:112-7. 2001
    ....
  48. ncbi Thiopurine S-methyltransferase as a target for drug interactions
    Hua Wen Xin
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376, Stuttgart, Germany
    Eur J Clin Pharmacol 61:395-8. 2005
    ..The present study was undertaken to investigate the possible effects of various agents on thiopurine methyltransferase (TPMT) activity in red blood cells (RBCs) from patients with chronic inflammatory bowel disease (IBD)...
  49. doi The clinical implications of ageing for rational drug therapy
    Shaojun Shi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Eur J Clin Pharmacol 64:183-99. 2008
    ..The proportion of the elderly is constantly increasing and by the year 2025 20% of the population will be above 65 years of age. With advanced age, subjects will develop multiple diseases and often need to take several drugs...
  50. doi Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results
    Martin Kimmel
    Martin Kimmel, Robert Bosch Hospital, Auerbachstr, 110, D 70376, Stuttgart, Germany
    Nephrol Dial Transplant 23:1241-5. 2008
    ..We investigated NAC and zinc (Zn) for the prevention of CIN by monitoring creatinine and cystatin C...
  51. ncbi Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection
    Frank Schönberger
    Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Stuttgart, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 768:255-60. 2002
    ..At all concentrations intra- and inter-assay variabilities were below 11% with less than 9% error. The method was applied to the determination of celecoxib for pharmacokinetic studies in man...
  52. ncbi Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects
    Karin Dilger
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    J Clin Pharmacol 42:985-94. 2002
    ..Therefore, normal aging appears not to represent a special risk factor in therapy with these two agents...
  53. ncbi P-glycoprotein function in the elderly
    Stefanie S Brenner
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Eur J Clin Pharmacol 60:97-102. 2004
    ....
  54. ncbi Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study)
    Gerhard Treiber
    Department of Gastroenterology Hepatology, University Hospital of Magdeburg, Leipziger Str 44, D 39120 Magdeburg, Germany
    Arch Intern Med 162:153-60. 2002
    ..Short-term therapies for eradicating Helicobacter pylori in selected patients might offer advantages in terms of costs, compliance, and adverse effects in contrast to standard 1-week triple therapy...
  55. ncbi Determinants of non-response in Helicobacter pylori eradication trials
    Ulrich Klotz
    J Gastroenterol Hepatol 20:1471. 2005
  56. ncbi Telomerase activity in chronic inflammatory bowel disease
    Elke Kleideiter
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, D 70376 Stuttgart, Germany
    Dig Dis Sci 48:2328-32. 2003
    ....
  57. ncbi Drug-related risks
    Ulrich Klotz
    Eur J Clin Pharmacol 63:983-4. 2007
  58. ncbi Tumorigenic conversion of endothelial cells
    Vera Krump-Konvalinkova
    Institute of Pathology, Johannes Gutenberg University Mainz, Germany
    Exp Mol Pathol 75:154-9. 2003
    ..This observation has implications for development of therapeutic approaches for angiosarcoma...
  59. ncbi Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic
    Gerhard Treiber
    Otto von Guericke University Hospital, Department of Gastroenterology Hepatology Infectious Diseases, Leipziger Str 44, D 39120 Magdeburg, Germany
    Expert Opin Pharmacother 8:329-50. 2007
    ..This review also highlights the impact of new drugs, new drug combinations, and their optimal dosing required to maximise clinical outcome...
  60. ncbi Drug interaction of herbal tea containing St. John's wort with cyclosporine
    Dominik Mark Alscher
    Transpl Int 16:543-4. 2003
  61. ncbi Transport studies with 5-aminosalicylate
    Hua Wen Xin
    Department of Clinical Pharmacology, Wuhan General Hospital, Wuhan, People s Republic of China
    Eur J Clin Pharmacol 62:871-5. 2006
    ..In addition to local metabolism of 5-ASA, it has been assumed that therapeutic mucosal concentrations of 5-ASA depend on transporter-mediated secretion back to the lumen...
  62. ncbi The elderly--a challenge for appropriate drug treatment
    Ulrich Klotz
    Eur J Clin Pharmacol 64:225-6. 2008